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1. Introduction {#sec1}
===============

HIV epidemics emerge first in specific subpopulations whose risk-behavior characteristics expose them to a higher risk of HIV infection ([@bib10]). In most countries, HIV epidemics remain concentrated in these high-risk subpopulations including men who have sex with men (MSM), people who inject drugs (PWID), and female sex workers (FSWs) and their clients ([@bib3]; [@bib24]; [@bib48]). Due to the generally hidden nature, social stigma, and legal persecution of these subpopulations, it is difficult to capture emerging HIV epidemics among them by conventional and passive surveillance systems ([@bib27]). Concentrated HIV epidemics in these high-risk groups are often detected years after epidemic emergence ([@bib32], [@bib36], [@bib35]). The delay in detecting epidemics as they emerge increases the risk of larger HIV epidemics emerging, and may limit access to HIV prevention services when needed ([@bib27]).

The Middle East and North Africa (MENA), for instance, is a region characterized by recently emerging HIV epidemics among MSM and PWID ([@bib32], [@bib36], [@bib35]), and to a lesser extent among FSWs and clients ([@bib3], [@bib4]). Most of HIV incidence appears to be occurring among these populations or their direct contacts (such as spouses of PWID or spouses of clients of FSWs) ([@bib21]; [@bib34], [@bib31]). Most epidemics in this region, extending from Morocco in the west to Pakistan and Afghanistan in the east, were discovered years after they emerged ([@bib32], [@bib36], [@bib35]). In Libya, for example, anecdotal evidence suggested the possibility of a large HIV epidemic among PWID since around 2000 ([@bib3], [@bib4]). Nevertheless, the stigma and marginalization of PWID prevented direct access to this population till recently, when it was discovered that Libya is enduring one of the largest HIV epidemics ever among PWID, at a prevalence of 87% ([@bib30]).

Novel surveillance methodologies have been developed to study HIV epidemiology among hidden and hard-to-reach populations ([@bib13]; [@bib17]; [@bib18]; [@bib27]; [@bib39]). Repeated integrated bio-behavioral surveillance surveys incorporating state of the art sampling methodologies for reaching hidden populations, such as respondent driven sampling, provide the best approach to study these key subpopulations ([@bib23]; [@bib20]). However, the commitment of national programs to working with such politically-sensitive populations is a persistent challenge ([@bib3], [@bib8]; [@bib14]; [@bib32]). These methodologies can also be costly to implement in resource-limited settings, and the technical expertise to conduct them may not be available. Even when implemented, in most cases they are executed infrequently preventing longitudinal inferences about the epidemics, and often applied only in select geographic areas ([@bib32], [@bib36]).

Against this background, we attempt here to answer the following question: Is it possible to identify emerging HIV epidemics among hidden and hard-to-reach high-risk subpopulations using routine and readily available HIV testing data such as those of blood donors among others (which are typically not used for surveillance purposes)? To address this question, we conducted hypothesis-generation modeling simulations to demonstrate this concept for HIV surveillance (study concept is illustrated in [Fig. 1](#fig1){ref-type="fig"}), thereby offering potentially a rapid and inexpensive methodology for detecting HIV epidemics as they emerge. If there are other supplementary data available, this approach may also be helpful to provide rough estimates for the epidemic growth rate and population size of the high-risk group, where the epidemic is expanding.Fig. 1**Concept of the study.** A schematic diagram of the use of routine HIV testing data to identify an emerging HIV epidemic in a high-risk subpopulation.Fig. 1

The utility of this approach hinges upon the availability of routine HIV testing data. While HIV testing of blood donors is available universally, and for different types of blood donation, different countries may have different protocols, and some may have stringent criteria for accepting blood donations that may exclude high-risk populations ([@bib41]). While we use blood donor data as an example of routine testing data, our approach can generically be applied for any type of routine HIV testing data.

Indeed, a main strength of the present study is the availability of a large volume of HIV testing data in MENA ([@bib3], [@bib4]; [@bib19]), the regional focus of our study. Though methodological HIV surveillance continues to be rather limited in this region ([@bib14]), there is (probably often unnecessarily) high emphasis on HIV testing of broad general populations ([@bib3]; [@bib19]). Reviews of current practices have indicated routine testing in diverse populations such as pregnant women, marriage applicants, university students, public sector employees, out-migrant (for visa to work abroad), in-migrants (for residency or visa renewal), prisoners, tuberculosis patients, and sexually transmitted disease clinic attendees ([@bib3]; [@bib19]). For instance, more than 53 million HIV tests have been conducted in MENA within a short time horizon ([@bib3]). As a specific country example, \>500,000 tests are routinely conducted in Qatar every year ([@bib29]), a country of less than three million inhabitants ([@bib28]). This volume of testing data in MENA is yet to be utilized for HIV surveillance or scientific analysis purposes.

2. Methods {#sec2}
==========

2.1. Mathematical model of an emerging HIV epidemic in a high-risk subpopulation {#sec2.1}
--------------------------------------------------------------------------------

### 2.1.1. Mathematical model structure {#sec2.1.1}

A deterministic dynamical mathematical model, based on extension and adaptation of earlier models ([@bib6]; [@bib5]), was constructed to describe HIV transmission in a given population. The model consisted of a system of coupled nonlinear differential equations that stratified the population according to HIV status, stage of infection, and risk group. HIV progression was represented by three stages: acute, latent, and advanced. The model was parameterized to represent an emerging epidemic in a hidden high-risk subpopulation such as MSM, but it can be generalized to represent other hidden subpopulations such as FSWs and clients and PWID.

The model describes an HIV epidemic in a population of 100,000 individuals, representative of a population of a metropolitan area. The population was divided into 20 risk groups, from lower to higher levels of risk behavior. It was assumed that most individuals belong to the lower risk groups (general populations), and the size of the high-risk subpopulation where the HIV epidemic is emerging (say MSM) did not exceed 1% of the total population.

To describe the mixing between different risk groups, we included a mixing matrix that incorporated both an assortative component (choosing partners only from within the same risk group), and a proportionate component (choosing partners with no preferential bias based on the risk group). HIV was introduced in the population in 1985, and the model simulated the spread of the infection over a period of 100 years.

Further details about the model structure can be found in the Supplementary Material (SM).

### 2.1.2. Model parameterization {#sec2.1.2}

The model was parameterized using quality natural history and epidemiological data for HIV. For example, the durations of the acute, latent, and advanced stages were assumed to be 49 days (acute), 9 years (latent), and 2 years (advanced). These choices were based on compilation of data by the Joint United Nations Programme on HIV/AIDS (UNAIDS) ([@bib42]; [@bib45],[@bib46]), and based on the classification in Wawer et al. ([@bib49]), re-analysis of the Rakai data for acute infection ([@bib38]), and measured time from seroconversion to death in cohort studies ([@bib45],[@bib46]). The model\'s parameter values along with their references are listed in [Table S1](#appsec2){ref-type="sec"} in SM. The risk of exposure to HIV infection in each risk group was parameterized by the effective partnership change rate of each risk group ([@bib11]; [@bib12]).

To simulate an emerging epidemic in the high-risk subpopulation that is *not sustainable* in the general population, the per-risk group effective partnership change rate was set to be large enough to generate a sustainable epidemic only in the four highest risk groups (risk groups 17--20). These risk groups represent different levels of risk behavior within the high-risk subpopulation. The remaining risk groups (risk groups 1--16) were considered as lower risk groups (general populations) in which the effective partnership change rate was not large enough to sustain an epidemic without mixing with the core high-risk subpopulation.

Further details about parameter assumptions can be found in SM.

### 2.1.3. Characterizing the actual epidemic using epidemiological summary measures {#sec2.1.3}

We estimated key epidemiological measures from the actual epidemic using the mathematical model such as HIV prevalence in the total population and HIV prevalence in the high-risk subpopulation. The trend of an epidemic is rather complex; therefore, to characterize the actual epidemic in terms of key epidemiological measures such as the time of epidemic emergence, epidemic growth rate, and time of epidemic saturation, we implemented a simple approach by fitting the actual epidemic to the following segmented linear model ([@bib47]):$$\text{HIV}\ \text{prevalence}\ \text{at}\ \text{time}\ t = \left\{ \begin{matrix}
c & {t \leq a} \\
{\beta\left( {t - a} \right) + c} & {a < t \leq b} \\
d & {t > b} \\
\end{matrix} \right.$$here, $c$ and $d$ are constants, the breakpoint $a$ is the time of epidemic emergence, $\beta$ is the epidemic growth rate, and the breakpoint $b$ is the time of epidemic saturation.

### 2.1.4. Additional epidemiological measures {#sec2.1.4}

Assuming the availability of other supplementary data, the approach proposed here can potentially provide rough estimates regarding additional epidemiological measures such as epidemic growth rate and population size of the high-risk subpopulation where the epidemic is emerging. To generate these estimations, we used an analytical approximation to link the epidemic growth rate in the total population with the epidemic growth rate *only* in the high-risk subpopulation. This link is expressed by the following equation:$$\mathit{\beta}_{T} \simeq frac_{HR}\mathit{\beta}_{HR}$$where $\mathit{\beta}_{T}$ is the epidemic growth rate in the total population, $\mathit{\beta}_{HR}$ is the epidemic growth rate in the high-risk subpopulation, and $frac_{HR}$ is the fraction of the population that belongs to the high-risk subpopulation. Derivation of this equation can be found in Section [3](#sec3){ref-type="sec"} of SM.

From this mathematical expression it is possible to roughly estimate the epidemic growth rate in the high-risk subpopulation, *if* the fraction of the population that belongs to the high-risk subpopulation is known. Likewise, it is possible to roughly estimate the population size of the high-risk subpopulation, *if* the epidemic growth rate in the high-risk subpopulation is known. Of notice that risk group size estimates can often be available, despite the limited availability of HIV data, as these data could have been generated for other purposes, such as the case for PWID whose estimates are often generated for drug-related purposes ([@bib36]). Moreover, even when such data are not available, regional or global estimates can be used as informed rough estimates of the size of the subpopulation, such as the case for MSM ([@bib16]; [@bib25]; [@bib26]; [@bib32]; [@bib42]).

2.2. Simulation of routine HIV testing data and AIDS case notifications {#sec2.2}
-----------------------------------------------------------------------

### 2.2.1. Stochastic Monte Carlo simulation of routine HIV testing and AIDS case notifications {#sec2.2.1}

We constructed a stochastic Monte Carlo simulation to simulate routine HIV testing data, such as those performed in different countries in populations including blood and organ donors, pregnant women, and marriage applicants among others ([@bib3]; [@bib19]). The simulation consisted of randomly sampling every year 2% (2000 individuals) of the total population, which is a good approximation of the percentage of individuals who donate blood per year ([@bib50]). For example, in high income countries such as those in North America and Europe, the average percentage of the population that donate blood is 3%; whereas in some MENA countries the average is between 1% and 2% ([@bib50]).

In the sampling process, it was assumed initially that each individual has the same probability of being sampled, independent of their risk group. Subsequently, as part of sensitivity analyses, we studied the effects of biases in the sampling process.

The sampling process was repeated 1000 times with the results reported as summary measures on these 1000 realizations.

### 2.2.2. Characterizing the sampled population using epidemiological summary measures {#sec2.2.2}

HIV prevalence and its 95% confidence interval (CI) were estimated for each sampled year and compared with the actual epidemic. The time of epidemic emergence and saturation as well as epidemic growth rate were also estimated from the sampled population by fitting the segmented linear model described in Equation [(1)](#fd1){ref-type="disp-formula"} to HIV prevalence time series.

We conducted, every year, a chi-square trend test on HIV prevalence time series up to that year, as estimated on the sampled population, to identify the temporal trend of HIV prevalence. We also conducted, every year, a chi-square trend test on AIDS case notifications time series up to that year, as also estimated on the sampled population, to identify the temporal trend in AIDS case notifications.

We recorded, for each statistical analysis, the earliest year in which the trend in HIV prevalence was found to be increasing with statistical significance. We also recorded, for each statistical analysis, the earliest year in which the trend in AIDS case notifications was found to be increasing with statistical significance. The latter represents passive surveillance of AIDS cases, as was common in the 1980s and 1990s, as a means to identify an emerging epidemic. This was done for merely comparison purposes, to highlight the differences with routine HIV testing surveillance. Of notice that AIDS surveillance refers here strictly to our ability to detect a statistically-significant trend of an emerging HIV epidemic using only AIDS cases.

### 2.2.3. Sensitivity analyses {#sec2.2.3}

Sensitivity analyses were conducted to evaluate the impact of variation in the routine HIV testing sample size (and AIDS case notifications), as well as biases in the sampling process, on the representativeness and accuracy of the epidemiological inferences based on the sampled population.

The biases in routine testing data can arise for different reasons, such as different testing protocols for different populations or regions, that may effectively underrepresent or overrepresent specific high-risk subpopulations ([@bib41]). The biases can also arise because of inherent differences in the underlying population, such as the differences between different blood donors---paid versus family replacement versus voluntary non-remunerated donors ([@bib1]; [@bib41]).

We conducted simulations with a smaller HIV testing sample size (1% of the total population instead of 2%), and larger sample size (5% of the total population instead of 2%). The effect of undersampling or oversampling the high-risk subpopulation was assessed by including a probability function in the random sampling process that underweighted, or overweighted the probability of randomly choosing an individual from the high-risk subpopulation.

3. Results {#sec3}
==========

3.1. Actual epidemic emerging in the high-risk subpopulation {#sec3.1}
------------------------------------------------------------

### 3.1.1. Epidemiological summary measures from the actual epidemic {#sec3.1.1}

HIV infection was introduced in the year 1985 in the high-risk subpopulation. The epidemic reached saturation at an HIV prevalence of 32% in the high-risk subpopulation ([Fig. 2](#fig2){ref-type="fig"}B), and at a prevalence of 0.33% in the total population ([Fig. 2](#fig2){ref-type="fig"}A). HIV prevalence in the four highest risk groups within the high-risk subpopulation ranged from 25% (risk group 17) to 48% (risk group 20) ([Fig. 2](#fig2){ref-type="fig"}C). The fraction of the high-risk subpopulation out of the total population (risk groups 17--20 combined) was 0.97% ([Fig. 2](#fig2){ref-type="fig"}D).Fig. 2**Epidemiological summary measures for the actual HIV epidemic.** A) HIV prevalence in the total population along with the segmented linear model fit. B) HIV prevalence in the high-risk subpopulation. C) HIV prevalence in the different risk groups in the population. D) Proportion of the population in each risk group.Fig. 2

We estimated from the segmented linear model fitting of the actual epidemic (using Equation [(1)](#fd1){ref-type="disp-formula"}, [Fig. 2](#fig2){ref-type="fig"}A) that the epidemic started its rapid epidemic phase 28 (95% CI 27--29) years after the introduction of the infection, and saturated 67 (95% CI 66--68) years after the introduction of the infection ([Fig. 2](#fig2){ref-type="fig"}A). The estimated epidemic growth rate of the actual epidemic in the total population was $8.4 \times 10^{- 3}\left( {95\%\ \text{CI}\ 8.2 \times 10^{- 3} - 8.7 \times 10^{- 3}} \right)$ per year, and in the high-risk subpopulation it was $0.84\left( {95\%\ \text{CI}\ 0.82 - 0.87} \right)$ per year---that is 100 times that in the total population.

### 3.1.2. Additional epidemiological measures {#sec3.1.2}

Assuming that the population size of the high-risk subpopulation is known from some other supplementary data source (here by design it was set in the model at about 1% of the total population), we can infer using Equation [(2)](#fd2){ref-type="disp-formula"} that the growth rate in this high-risk subpopulation $\mathit{\beta}_{HR}$ is equal to 0.84 per year. Alternatively, assuming that the growth rate in the high-risk subpopulation $\left( \mathit{\beta}_{HR} \right)$ is what is known from some other supplementary data, then we can infer using Equation [(2)](#fd2){ref-type="disp-formula"} that the population size of the high-risk subpopulation is about 1% of the total population.

3.2. Simulation of routine HIV testing data and AIDS case notifications {#sec3.2}
-----------------------------------------------------------------------

### 3.2.1. Epidemiological summary measures from the sampled population {#sec3.2.1}

[Fig. 3](#fig3){ref-type="fig"} shows HIV prevalence and its corresponding 95% CI in the population sample generated by the simulated stochastic HIV routine testing on the total population (such as blood donation). [Fig. 3](#fig3){ref-type="fig"}A demonstrates that the sample-estimated HIV prevalence was representative of HIV prevalence in the actual epidemic. For the year 2013, when the epidemic started its rapid epidemic phase, HIV prevalence in the sample was 0.031% (95% CI 0.013%--0.079%), whereas HIV prevalence in the actual epidemic was 0.039%. Sometime during the rapid growing phase of the epidemic, for example in the year 2032, HIV prevalence in the sample was 0.16% (95% CI 0.11%--0.24%), whereas HIV prevalence in the actual epidemic was 0.18%. For the year 2052, the year when the epidemic saturated, HIV prevalence in the sample was 0.32% (95% CI 0.26%--0.41%), whereas HIV prevalence in the actual epidemic was 0.33%.Fig. 3**Epidemiological measures for the simulated routine HIV testing sampled population.** A) Mean and 95% confidence interval of the HIV prevalence time series estimated from the sampled population (red boxes), compared to HIV prevalence in the actual epidemic (blue line). B) The segmented linear model fit of HIV prevalence time series as estimated from the sampled population (red boxes). All of these results are for the total population.Fig. 3

The segmented linear model fitting for the population sample is illustrated in [Fig. 3](#fig3){ref-type="fig"}B. The time after infection introduction but before epidemic emergence was estimated at 28 years (95% CI 25--32) ([Table 1](#tbl1){ref-type="table"})---the same year \[28 (95% CI 27--29)\] as estimated from fitting the actual epidemic ([Fig. 2](#fig2){ref-type="fig"}A and [Table 1](#tbl1){ref-type="table"}). Epidemic saturation was reached 66 years (95% CI 62--70) after infection introduction---close to the year \[67 (95% CI 66--68)\] as estimated from fitting the actual epidemic ([Fig. 2](#fig2){ref-type="fig"}A and [Table 1](#tbl1){ref-type="table"}). The epidemic growth rate in the total population was $8.4 \times 10^{- 3}\left( {95\%\ \text{CI}\ 7.2 \times 10^{- 3} - 9.9 \times 10^{- 3}} \right)$ per year---similar to the epidemic growth rate estimated from fitting the actual epidemic \[$8.4 \times 10^{- 3}\left( {95\%\ \text{CI}\ 8.2 \times 10^{- 3} - 8.7 \times 10^{- 3}} \right)$ per year\] ([Fig. 2](#fig2){ref-type="fig"}A and [Table 1](#tbl1){ref-type="table"}).Table 1Estimated measures using the segmented linear model fitting of the actual epidemic and the simulated routine HIV testing sampled population. The Table includes also the results of the sensitivity analyses.Table 1Number of years to epidemic emergence after HIV introduction (95% CI)Number of years to epidemic saturation after HIV introduction ~(95%\ CI)~Epidemic growth rate (95% CI)Actual epidemic in the total population28 (27--29)~67\ (66--68)~$8.4 \times 10^{- 3}$$\left( {8.2 \times 10^{- 3} - 8.7 \times 10^{- 3}} \right)$Simulated routine HIV testing sampled population (2% of the total population)28 (25--32)~66\ (62--70)~$8.4 \times 10^{- 3}$$\left( {7.2 \times 10^{- 3} - 9.9 \times 10^{- 3}} \right)$Sensitivity analysis of smaller sample size for the simulated routine HIV testing sampled population (1% of the total population)29 (24--34)~68\ (63--72)~$8.6 \times 10^{- 3}$$\left( {6.8 \times 10^{- 3} - 10.7 \times 10^{- 3}} \right)$Sensitivity analysis of larger sample size for the simulated routine HIV testing sampled population (5% of the total population)28 (26--30)~67\ (66--69)~$8.5 \times 10^{- 3}$$\left( {7.7 \times 10^{- 3} - 9.3 \times 10^{- 3}} \right)$Sensitivity analysis of undersampling the high-risk subpopulation in the simulated routine HIV testing sampled population29 (25--35)~66\ (61--72)~$4.5 \times 10^{- 3}$$\left( {3.5 \times 10^{- 3} - 5.6 \times 10^{- 3}} \right)$Sensitivity analysis of oversampling the high-risk subpopulation in the simulated routine HIV testing sampled population28 (26--30)~67\ (65--70)~$1.7 \times 10^{- 2}$$\left( {1.5 \times 10^{- 2} - 1.9 \times 10^{- 2}} \right)$

[Fig. 4](#fig4){ref-type="fig"} shows the year of epidemic identification (after epidemic emergence) using the HIV prevalence times series generated using the routine HIV testing, versus the year of epidemic identification using the time series of AIDS case notifications. Using routine HIV testing, the emerging epidemic was identified (with statistical significance) 4.0 (95% CI 3.4--4.6) years after epidemic emergence. Meanwhile, using AIDS case notifications, the emerging epidemic was identified (with statistical significance) 29.7 (95% CI 15.8--52.1) years after epidemic emergence. Across the 1000 realizations, routine HIV testing identified the emerging epidemic 24.3 (95% CI: 11.9--49.8) years before AIDS case notifications.Fig. 4**Epidemic identification time.** Mean and 95% confidence interval of the year of detecting the epidemic after epidemic emergence using the routine HIV testing sampled population versus using AIDS cases notification.Fig. 4

### 3.2.2. Sensitivity analyses {#sec3.2.2}

None of the sampling biases included in this study affected the conclusion of an emerging epidemic ([Table 1](#tbl1){ref-type="table"}). However, some of the biases, such as undersampling or oversampling, the high-risk subpopulation affected (to some degree or another) some of the estimated epidemiological measures, in particular (understandably) the epidemic growth rate ([Table 1](#tbl1){ref-type="table"}). Importantly, none of the sampling biases affected appreciably the year of epidemic identification as estimated using the routine HIV testing, but these biases generally affected the year of epidemic identification as estimated using AIDS case notifications ([Fig. 5](#fig5){ref-type="fig"}).Fig. 5**Sensitivity analyses on the time of detecting the epidemic after epidemic emergence.** A) Assuming a smaller sample size for the simulated routine HIV testing (1% of the total population). B) Assuming a larger sample size for the simulated routine HIV testing (5% of the total population). C) Assuming undersampling of the high-risk subpopulation in the simulated routine HIV testing. D) Assuming oversampling of the high-risk subpopulation in the simulated routine HIV testing.Fig. 5

4. Discussion {#sec4}
=============

The aim of this study was to demonstrate, using mathematical modeling, the concept of using routine HIV testing data (such as those of blood donors ([@bib19])) to identify a hidden HIV epidemic in some hard-to-reach high-risk subpopulation. We found that simple analyses on HIV testing data (of no methodological complexity) can provide a useful tool to identify such hidden epidemic, thereby supporting HIV surveillance efforts at a low cost that can be affordable even in resource-limited settings. We also found that this approach can identify the hidden epidemic rapidly, within at most few years of epidemic emergence, and much earlier than that of a surveillance based on AIDS case notifications. Use of routine HIV testing data can demonstrate to policymakers the emergence of an epidemic, thereby supporting advocacy for investment in HIV surveillance and intervention response.

Despite the limitations of HIV testing data, the presented analyses demonstrate that these data are of utility and can capture, despite some caveats and limitations, key temporal patterns of a hidden HIV epidemic in a hard-to-reach subpopulation. With availability of other supplementary data sources, such as HIV case notifications (which are routine across countries) ([@bib15]; [@bib22]; [@bib33], [@bib35]), and data on proxy biomarkers of risk behavior (such as prevalence of different sexually transmitted infections for sexual high-risk groups, or prevalence of hepatitis C virus for PWID) ([@bib7]; [@bib9]; [@bib37]; [@bib47]), the utility of this approach is enhanced and can be used to identify the specific high-risk subpopulation affected by the epidemic. It can also provide estimates for a wider set of epidemiological measures, such as high-risk subpopulation size estimates, growth rate of the epidemic in the high-risk subpopulation, and HIV epidemic potential.

An example to this end is the use of recently-notified HIV cases to identify the population affected by the epidemic, as suggested for the epidemic among MSM in Oman and Syria, and the epidemic among PWID in Saudi Arabia ([@bib35]). Similarly, the presented approach can also supplement other sources of data, such as those of the integrated bio-behavioral surveillance surveys ([@bib14]), to provide a more comprehensive characterization of the epidemiology of HIV in a given population.

These findings are specially relevant in countries at low HIV prevalence, such as many of the countries in the MENA region ([@bib3], [@bib4]; [@bib32], [@bib36], [@bib35]), where there has been overall limited national commitment to HIV surveillance ([@bib2]; [@bib3]; [@bib14]; [@bib40]), in part because of the high stigma associated with HIV ([@bib3]; [@bib40]). The HIV epidemics in this region emerged mostly during the last decade and have not yet reached their peak ([@bib3], [@bib4]; [@bib32], [@bib36], [@bib35]). Existing evidence suggests considerable HIV epidemic potential in high-risk subpopulations in this region ([@bib7]; [@bib9]; [@bib37]). Importantly, many of the epidemics, such as those among PWID in Libya and Pakistan ([@bib30]; [@bib36]), were discovered years after epidemic emergence ([@bib32], [@bib36], [@bib35]). Indeed, there is already anecdotal evidence that suggests ongoing emerging HIV epidemics in several countries which are yet to be documented, characterized, and tackled ([@bib35]). With the approach proposed here, such potential epidemics could be detected early, overcoming some of the complexities and difficulties of directly monitoring epidemics in hidden and hard-to-reach subpopulations ([@bib2]; [@bib3], [@bib8]).

Our study has limitations. We presented an approach for detecting emerging HIV epidemics, but other approaches could also be possible and should be investigated, such as using antiretroviral therapy (ART) programs to monitor trends---an approach that may not yet be feasible given the low ART coverage in MENA, the lowest globally at only 17% in 2015 ([@bib43]). While our proposed approach can provide qualitative characterization of hidden epidemics, it may only provide rough quantitative estimates for several of the epidemiologic measures. The provided estimates may not also be sufficient to establish a meaningful characterization of an emerging epidemic without other supplementary data, such as case notifications, to identify the affected population. Routine HIV testing data can be subject to multiple biases, and the nature of bias may vary by time and geographic location, as well as by country, thereby introducing challenges in generating epidemiological inferences.

The model used here was strictly designed to describe HIV sexual transmission, but the essential concept of this study relies merely on the generic existence of an emerging epidemic. Accordingly, the findings are applicable for epidemics among PWID. Indeed, the often rapidly-rising epidemics among PWID ([@bib36]), are even easier to discern with this approach, as the growth rate of HIV prevalence is faster.

Epidemic dynamics can be complex whereby several epidemics could be emerging simultaneously in different high-risk subpopulations, further complicating the generation of epidemiological inferences. We did not factor ART coverage in the model, but this may not have affected our results, as we focused on emerging epidemics where ART coverage is yet to be scaled up.

Despite these limitations, our results suggest that this approach can be effective and easy to implement. The sensitivity analyses we conducted, to explore the impact of several such limitations, also supported the value of this approach.

5. Conclusions {#sec5}
==============

Using hypothesis-generation modeling, we demonstrated the concept of using routine HIV testing data to identify and characterize hidden and emerging HIV epidemics in high-risk subpopulations. This approach can be easily implemented and requires limited resources, and can be applied alone, or along with other complementary data sources to provide a meaningful characterization of hidden epidemics. The approach also avoids challenges and difficulties of HIV surveillance among stigmatized, hidden, and hard-to-reach subpopulations. It would be pertinent as a next step to explore an application of this approach in a country that has sufficient data on high-risk subpopulations, along with different sources of routine HIV testing data, to empirically validate this concept and explore strengths and limitations of this approach. Lastly, our study demonstrates mathematical modeling as a powerful tool to investigate theoretical concepts for the development of programs and policies towards addressing difficult public health challenges and priorities.
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